- Home
- PBFS vs TSHA Comparison
PBFS vs TSHA Comparison
Compare PBFS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- TSHA
- Stock Information
- Founded
- PBFS 1889
- TSHA 2019
- Country
- PBFS United States
- TSHA United States
- Employees
- PBFS N/A
- TSHA N/A
- Industry
- PBFS Banks
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- TSHA Health Care
- Exchange
- PBFS Nasdaq
- TSHA Nasdaq
- Market Cap
- PBFS 309.6M
- TSHA 356.7M
- IPO Year
- PBFS N/A
- TSHA 2020
- Fundamental
- Price
- PBFS $11.78
- TSHA $1.77
- Analyst Decision
- PBFS
- TSHA Strong Buy
- Analyst Count
- PBFS 0
- TSHA 8
- Target Price
- PBFS N/A
- TSHA $6.63
- AVG Volume (30 Days)
- PBFS 26.6K
- TSHA 1.5M
- Earning Date
- PBFS 05-12-2025
- TSHA 05-13-2025
- Dividend Yield
- PBFS N/A
- TSHA N/A
- EPS Growth
- PBFS 11.77
- TSHA N/A
- EPS
- PBFS 0.76
- TSHA N/A
- Revenue
- PBFS $88,118,000.00
- TSHA $8,333,000.00
- Revenue This Year
- PBFS N/A
- TSHA N/A
- Revenue Next Year
- PBFS N/A
- TSHA N/A
- P/E Ratio
- PBFS $15.61
- TSHA N/A
- Revenue Growth
- PBFS 21.67
- TSHA N/A
- 52 Week Low
- PBFS $8.76
- TSHA $1.19
- 52 Week High
- PBFS $12.20
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- PBFS 54.69
- TSHA 59.56
- Support Level
- PBFS $11.77
- TSHA $1.71
- Resistance Level
- PBFS $12.04
- TSHA $1.82
- Average True Range (ATR)
- PBFS 0.24
- TSHA 0.09
- MACD
- PBFS -0.01
- TSHA 0.02
- Stochastic Oscillator
- PBFS 54.24
- TSHA 82.76
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.